Literature DB >> 12494431

Risk perception of participants in a family-based genetic screening program on familial hypercholesterolemia.

M C van Maarle1, M E A Stouthard, G J Bonsel.   

Abstract

The aim of this article is threefold. First, we describe the accuracy of people's risk perception who have been screened on familial hypercholesterolemia (FH) in a family-based screening program. Second, we identify factors that modify risk perception. Finally, we show the influence of risk perception on subsequent preventive behavior. The risk perception of 556 screenees (677 participants, overall response = 82%) was measured by postal questionnaires on three occasions: at screening and 3 days and 7 months after the test result was reported to the patient. Presentation of the risk was precategorized and given both as numerical (1 in x) and as verbal probability. In addition, medication use and attitudes toward gene therapy were determined 7 months after screening. On average, the screenees underestimated their numeric risk of having FH and getting a myocardial infarction (MI). Furthermore, FH-positive screenees perceived that they were at greater risk of MI than FH negatives, and screenees with the highest actual risk used medication more, perceived a greater risk, and opted more often for future gene therapy. Risk perception of having FH was influenced by cholesterol level, while MI risk perception was affected by age, education, cholesterol level, and cardiovascular disease (CVD) in the family. We conclude that FH-positive screenees correctly perceive a higher risk of getting a heart attack than do FH-negative screenees. Screenees did not believe that MI was inevitable, and risk perception was associated with both medication use and the intention to opt for gene therapy, but not with other preventive measures. Thus, genetic risk notification seems to be acceptable and does not lead to aversion to preventive behavior. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2003        PMID: 12494431     DOI: 10.1002/ajmg.a.10061

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  8 in total

1.  "Awakening to" a new meaning of being at-risk for arrhythmogenic right ventricular cardiomyopathy: a grounded theory study.

Authors:  April Manuel; Fern Brunger
Journal:  J Community Genet       Date:  2015-01-27

2.  Perceived vulnerability to heart disease in patients with familial hypercholesterolemia: a qualitative interview study.

Authors:  Jan C Frich; Leiv Ose; Kirsti Malterud; Per Fugelli
Journal:  Ann Fam Med       Date:  2006 May-Jun       Impact factor: 5.166

3.  A tailored lifestyle intervention to reduce the cardiovascular disease risk of individuals with Familial Hypercholesterolemia (FH): design of the PRO-FIT randomised controlled trial.

Authors:  Karen Broekhuizen; Mireille N M van Poppel; Lando L J Koppes; Johannes Brug; Willem van Mechelen
Journal:  BMC Public Health       Date:  2010-02-15       Impact factor: 3.295

Review 4.  Strategies for screening for familial hypercholesterolaemia in primary care and other community settings.

Authors:  Nadeem Qureshi; Maria Luisa R Da Silva; Hasidah Abdul-Hamid; Stephen F Weng; Joe Kai; Jo Leonardi-Bee
Journal:  Cochrane Database Syst Rev       Date:  2021-10-07

5.  Patients' perceptions and experiences of familial hypercholesterolemia, cascade genetic screening and treatment.

Authors:  Sarah J Hardcastle; Ellen Legge; Chris S Laundy; Sarah J Egan; Rosemary French; Gerald F Watts; Martin S Hagger
Journal:  Int J Behav Med       Date:  2015-02

6.  Predicting Self-Management Behaviors in Familial Hypercholesterolemia Using an Integrated Theoretical Model: the Impact of Beliefs About Illnesses and Beliefs About Behaviors.

Authors:  Martin S Hagger; Sarah J Hardcastle; Catherine Hingley; Ella Strickland; Jing Pang; Gerald F Watts
Journal:  Int J Behav Med       Date:  2016-06

7.  Self-rated cardiovascular risk and 15-year cardiovascular mortality.

Authors:  Robert Gramling; William Klein; Mary Roberts; Molly E Waring; David Gramling; Charles B Eaton
Journal:  Ann Fam Med       Date:  2008 Jul-Aug       Impact factor: 5.166

8.  Enablers and barriers to treatment adherence in heterozygous familial hypercholesterolaemia: a qualitative evidence synthesis.

Authors:  Fiona J Kinnear; Elaine Wainwright; Rachel Perry; Fiona E Lithander; Graham Bayly; Alyson Huntley; Jennifer Cox; Julian Ph Shield; Aidan Searle
Journal:  BMJ Open       Date:  2019-07-31       Impact factor: 2.692

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.